Loading companies…
Loading companies…
United States · Biotech · Enterprise software
Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Growth | $60M | AMR Action Fund — Role not disclosedBARDA — Role not disclosedBNP Paribas Asset Management Alts — Role not disclosed |